

**Listing of Claims**

1. (original) A substantially purified RFX4\_v3 polypeptide.
2. (original) The polypeptide of claim 1, wherein the polypeptide comprises:
  - a) an amino acid sequence at least 70% identical to an amino acid sequence set forth as SEQ ID NO: 8;
  - b) a conservative variant of the amino acid sequence set forth as SEQ ID NO: 8; or
  - c) the amino acid sequence set forth as SEQ ID NO: 8,  
wherein the polypeptide has RFX4\_v3 activity, and the N-terminus of the polypeptide is at least 90% identical to residues 1-14 of SEQ ID NO: 8.
3. (original) The polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence set forth as SEQ ID NO: 6, or SEQ ID NO: 10.
4. (original) The polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence set forth as SEQ ID NO: 8, or a sequence having at least 95% sequence identity to SEQ ID NO: 8.
5. (original) An isolated nucleic acid molecule encoding the polypeptide of claim 2.
6. (original) The nucleic acid of claim 5, wherein the nucleic acid molecule comprises:  
a nucleic acid sequence at least 70% identical to the nucleic acid sequence set forth as SEQ ID NO: 37.
7. (original) The nucleic acid of claim 6, wherein the nucleic acid sequence is at least 90% identical to SEQ ID NO: 38 or SEQ ID NO: 39.
8. (original) The nucleic acid of claim 6, wherein the nucleic acid sequence is at least 90% identical to SEQ ID NO: 37.
9. (original) The nucleic acid sequence of claim 5, wherein the nucleic acid sequence is operably linked to a heterologous promoter.

10. (original) The nucleic acid sequence of claim 5, wherein the heterologous promoter comprises SEQ ID NO: 11 or SEQ ID NO: 12.

11. (original) A vector comprising the nucleic acid of claim 5.

12. (original) A host cell transformed with the vector of claim 11.

13. (original) The host cell of claim 12, wherein the host cell is a plant cell, an animal cell, or a prokaryotic cell.

14. (original) A composition comprising the polypeptide of claim 2.

15. (currently amended) An isolated nucleic acid molecule that hybridizes under conditions of low stringency to a ~~target nucleic acid molecule~~polynucleotide comprising nucleotides 1-42 of a nucleic acid sequence selected from the group consisting of ~~nucleotides 1-42 of~~ SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39, wherein the isolated nucleic acid molecule ~~is~~comprises at least 15 nucleotides in length.

16. (currently amended) The isolated nucleic acid molecule of claim 15, ~~that wherein the isolated nucleic acid molecule~~ hybridizes under conditions of high stringency to the ~~target nucleic acid molecule~~polynucleotide.

17. (currently amended) The nucleic acid of claim 15, wherein the ~~target~~isolated nucleic acid molecule encodes a RFX4\_v3 polypeptide.

18. (currently amended) The nucleic acid of claim ~~12~~17, wherein the RFX4\_v3 polypeptide comprises SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

19. (original) A vector comprising the nucleic acid of claim 15.

20. (original) A host cell transformed with the vector of claim 19.

21. (original) The host cell of claim 20, wherein the host cell is a plant cell, an animal cell, or a prokaryotic cell.

22. (original) The polypeptide of claim 2, wherein the RFX4\_v3 activity comprises inhibiting the phenotypic expression of congenital hydrocephalus.

23. (original) The polypeptide of claim 2, wherein the activity is the ability to bind to RFX4\_v3 specific antibodies.

24. (original) The polypeptide of claim 2, wherein the polypeptide comprises the amino acid residues set forth in SEQ ID NO: 33, SEQ ID NO: 34, or SEQ ID NO: 35.

25. (currently amended) A method for producing a variant of thea RFX4\_v3 polypeptide of claim 1, wherein the method comprises:

mutagenizing the-a wild-type nucleic acid sequence ~~of as set forth in~~ SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39; and

screening the variant for a RFX4\_v3 activity to identify the variant of the RFX4\_v3 polypeptide.

26. (currently amended) A composition comprising a nucleic acid molecule that inhibits the binding of the polynucleotide of claim 15 first 42 nucleotides of SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39 to its complementary sequence.

27. (currently amended) A polynucleotide sequence comprising at least fifteen nucleotides ~~The isolated nucleic acid of claim 15, wherein the isolated nucleic acid hybridizes capable of hybridizing under stringent conditions to an isolated nucleotide sequence to the polynucleotide comprising nucleotides 1-42 of SEQ ID NO: 37.~~

28. (currently amended) A method for detecting a nucleic acid molecule in a biological sample, ~~wherein the nucleic acid molecule encodes a RFX4\_v3 polypeptide, the method comprising:~~  
~~hybridizing a polynucleotide to the nucleic acid molecule to produce a hybridization complex,~~  
~~wherein the nucleic acid molecule encodes the RFX4\_v3 polypeptide of claim 1 and wherein the polynucleotide hybridizes to nucleotides 1-42 of SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39;~~

detecting the hybridization complex, wherein the presence of the hybridization complex indicates the presence of a polynucleotide the nucleic acid molecule encoding RFX4\_v3 in the biological sample, thereby detecting the nucleic acid molecule in the biological sample.

29. (original) The method of claim 28, wherein the polynucleotide hybridizes to SEQ ID NO: 37.

30. (currently amended) The method of claim 3028, further comprising amplifying the nucleic acid molecule prior to hybridizing with the polynucleotide.

31. (currently amended) A method of identifying a subject at risk of developing RFX4\_v3 linked hydrocephalus, comprising detecting in the subject an abnormality a mutation in a the RFX4\_v3 polypeptide of claim 1 or a mutation in a RFX4\_v3 nucleotide sequence, wherein the mutation in the nucleotide sequence that alters expression of the RFX4\_v3 polypeptide, thereby identifying a subject at risk of developing RFX4\_v3 linked hydrocephalus.

32. (canceled) The method of claim 31, wherein detecting an abnormality comprises detecting a mutation in a nucleic acid sequence that encodes RFX4\_v3, wherein the mutation is associated with RFX4\_v3 linked hydrocephalus.

33. (currently amended) The method of claim 31, wherein detecting an abnormality the mutation in the RFX4\_v3 nucleotide sequence nucleic acid comprises performing a hybridization analysis with a nucleic acid probe that detects the mutation in the RFX4\_v3 nucleic acid sequence.

34. (currently amended) The method of claim 31, wherein detecting an abnormality the mutation comprises identifying an individual carrying a mutated RFX4\_v3 allele, wherein the method comprises: providing a nucleic acid from a the subject, wherein the nucleic acid comprises a RFX4\_v3 allele; and

detecting a mutation in the nucleic acid that results in phenotypic expression of congenital hydrocephalus.

35. (original) The method of claim 34, wherein the mutation is in the RFX4\_v3 allele.

36. (currently amended) The method of claim 31, wherein the method comprises detecting an abnormality~~the mutation~~ in a~~the~~ RFX4\_v3 polypeptide.

37. (original) The method of claim 36, wherein the method comprises detecting an abnormality in expression of the RFX4\_v3 polypeptide.

38. (currently amended) The method of claim 37, wherein the abnormality in expression ~~comprises detecting~~method detects a reduced expression of the RFX4\_v3 polypeptide.

39. (currently amended) The method of claim 36, wherein the method comprises providing a polypeptide from a~~the~~ subject, and detecting a mutation in the sequence encoding the polypeptide sequence, ~~wherein the polypeptide comprises the RFX4\_v3 polypeptide and~~ wherein the mutation results in phenotypic expression of congenital hydrocephalus.

40. (currently amended) The method of claim 31, comprising obtaining a biological sample from the subject, and detecting in the biological sample the abnormality~~mutation~~ in the RFX4\_v3 polypeptide or in the RFX4\_v3 nucleotide sequence.

41. (original) The method of claim 40, wherein the biological sample comprises blood, amniotic fluid, plasma, or cerebral spinal fluid.

42. (canceled) ~~The method of claim 40, wherein the method comprises: providing a polypeptide from a subject, wherein the polypeptide comprises a gene product of a RFX4\_v1 gene; and detecting a mutation in the polypeptide sequence, wherein the mutation results in phenotypic expression of congenital hydrocephalus.~~

43. (original) The method of claim 4238, wherein detecting ~~the mutation in the polypeptide sequence~~ comprises detecting an abnormal protein or the reduced level or protein expression of the RFX4\_v3 polypeptide ~~comprises~~ using RFX4\_v1 specific antibodies.

44. (original) A kit for determining if a subject is a carrier of a mutated RFX4\_v3 gene, wherein the kit comprises:

a reagent that specifically detects a mutation in a RFX4\_v3 allele, and  
instructions for determining whether the subject is at increased risk of expressing congenital  
hydrocephalus if the reagent specifically detects the mutation.

45. (original) The kit of claim 44, wherein the reagent comprises a nucleic acid probe that  
specifically hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 37, SEQ ID  
NO: 38 or SEQ ID NO: 39.

46. (original) The kit of claim 44, wherein the reagent comprises an antibody that specifically  
binds the protein expressed by the RFX4\_v3 allele.

47. (canceled) ~~A method for generating antibodies specific for an RFX4\_v3 polypeptide, wherein  
the method comprises injecting an animal with an RFX4\_v3 polypeptide or an immunogenic portion  
thereof.~~

48. (canceled) ~~The method of claim 47, further comprising preparing a hybridoma that expresses  
the monoclonal antibody.~~

49. (currently amended) An antibody that specifically binds the polypeptide of claim 1~~RFX4\_v3~~  
~~specific antibody for use as a detection or therapeutic agent.~~

50. (original) A method for generating a non-human transgenic animal with a knockout for the  
RFX4\_v3 gene, wherein the method comprises disrupting an RFX4\_v3 transcript, the disruption being  
sufficient to produce hydrocephalus in the transgenic animal.

51. (original) The method of claim 50, wherein the non-human transgenic animal is a mouse.

52. (original) The method of claim 50, wherein disrupting a RFX4\_v3 transcript comprises:  
deleting or substituting any portion of the RFX4\_v3 transcript,  
inserting an exogenous gene into the RFX4\_v3 transcript, or  
any combination thereof.

53. (original) The method of claim 50, wherein disrupting the RFX4\_v3 transcript comprises crossing one non-human transgenic animal with a second non-human transgenic animal.

54. (original) A transgenic mouse whose somatic and germ cells comprise a disrupted endogenous RFX4\_v3 gene, the disruption being sufficient to produce an increased susceptibility to developing congenital hydrocephalus.

55. (original) The transgenic mouse of claim 54, wherein the disrupted gene is introduced into the mouse of an ancestor of the mouse at an embryonic stage, wherein the mouse, if homozygous for the disrupted gene, does not reproduce.

56. (original) The transgenic mouse of claim 54, wherein the disruption is an insertion within the RFX4\_v3 gene.

57. (original) The composition of claim 54, wherein the disruption is a deletion or substitution within the RFX4\_v3 gene.

58. (currently amended) A method for screening compounds for the ability to alter RFX4\_v3 activity, wherein the method comprises:

- a) providing:
  - i) a first polypeptide sequence comprising at least a portion of ~~RFX4\_v3~~ the polypeptide of claim 1,
  - ii) a second polypeptide sequence comprising at least a portion of a protein known to interact with RFX4\_v3, and
  - iii) one or more test compounds; and
- b) combining in any order ~~the first polypeptide sequence comprising at least a portion of RFX4\_v3, the second polypeptide sequence comprising at least a portion of a protein known to interact with RFX4\_v3, and one or more test compounds~~ (i), (ii), and (iii) under conditions such that the first polypeptide sequence, the second polypeptide sequence, and the test compound interact; and
- c) detecting the presence or absence of an interaction between the ~~first polypeptide sequence comprising at least a portion of RFX4\_v3 and the second polypeptide sequence comprising at least a portion of a protein known to interact with RFX4\_v3~~.

59. (currently amended) A pharmaceutical composition, for treating congenital hydrocephalus comprising:

- a) a therapeutically effective amount of a RFX4\_v3 nucleic acid, the polypeptide of claim 1, a nucleic acid sequence encoding the polypeptide, or a therapeutically effective variant or portion thereof; and
- b) a pharmaceutically acceptable carrier.

60. (canceled) A pharmaceutical composition for preventing congenital hydrocephalus comprising:

- a) a RFX4\_v3 nucleic acid, polypeptide, a variant, or a portion thereof, and
- b) a pharmaceutically acceptable carrier.

61. (currently amended) A method of treating congenital hydrocephalus in a subject, comprising administering to the subject a therapeutically effective amount of an agent that increases presence of a RFX4\_v3 polypeptide in the brain of to the subject.

62. (original) The method of claim 61, wherein the method comprises administering exogenous RFX4\_v3 polypeptide to the subject.

63. (original) The method of claim 61, wherein the method comprises increasing expression of RFX4\_v3 polypeptide in the subject.

64. (original) The method of claim 63, wherein the method comprises introducing into the subject a vector that expresses the RFX4\_v3 polypeptide in the subject.